#VISIONtrial - Twitter Hashtag

about 2 months ago

Impact of external beam radiotherapy use and timing on clinical outcomes in patients receiving 177Lu-PSMA-617 + best Standard of Care: a secondary analysis from the #VISIONTrial. Presentation by Abigail Pepin, MD @PennCancer. #SNMMI26 written coverage by @zklaassen_md @GACancerCenter > https://t.co/AFVYHm9TPW @SNM_MI

urotoday's tweet photo. Impact of external beam radiotherapy use and timing on clinical outcomes in patients receiving 177Lu-PSMA-617 + best Standard of Care: a secondary analysis from the #VISIONTrial. Presentation by Abigail Pepin, MD @PennCancer. #SNMMI26 written coverage by @zklaassen_md @GACancerCenter > https://t.co/AFVYHm9TPW @SNM_MI

0

11

7

4

975

Jeremie Calais @CalaisJeremie

over 4 years ago

Patients who do not meet the #PSMA PET/CT eligibility criteria used in the #VISIONtrial and who are treated with #LutetiumPSMA do not respond well to treatment with a PSA50RR of 20%. #Biomarker #prostatecancer #theranostics #PETimaging https://t.co/PzSUB0LO1p

CalaisJeremie's tweet photo. Patients who do not meet the #PSMA PET/CT eligibility criteria used in the #VISIONtrial and who are treated with #LutetiumPSMA do not respond well to treatment with a PSA50RR of 20%. #Biomarker #prostatecancer #theranostics #PETimaging
https://t.co/PzSUB0LO1p https://t.co/99s6cDbsAs

1

40

10

3

0

Advanced Prostate Cancer Consensus Conference

@APCCC_Lugano

over 4 years ago

Preliminary #APCCC21 results of Expert Vote: #Consensus Question Nr #78 #LuPSMA #VisionTrial 🎥 All expert session recordings are available online, access w/ your credentials: https://t.co/uOrGrDUYY4 Register for #APCCC22 and get access, too: https://t.co/V6e42WoOwI #urology

APCCC_Lugano's tweet photo. Preliminary #APCCC21 results of Expert Vote: #Consensus Question Nr #78 #LuPSMA #VisionTrial

🎥 All expert session recordings are available online, access w/ your credentials: https://t.co/uOrGrDUYY4

Register for #APCCC22 and get access, too: https://t.co/V6e42WoOwI

#urology https://t.co/M3z0uNs1kn

0

3

0

1

0

Alex Hermen @AlexHermen

almost 5 years ago

#VISIONtrial Radioligand therapy with #177Lu ☢ in #mCRPC 👥 831 PSMA+ ⏳Follow-up 20.9 m 🧐177LuPSMA617 + SC vs SC alone 💡177LuPSMA617 ⬆️ imaging based PFS (8.7 vs 3.4 m) HR for progression or ☠ 0.40 ⬆️ OS (15.3 vs 11.3 mo) HR for ☠ 0.62 ⬆️ AE but QoL was not affected

AlexHermen's tweet photo. #VISIONtrial Radioligand therapy with #177Lu ☢ in #mCRPC
👥 831 PSMA+
⏳Follow-up 20.9 m
🧐177LuPSMA617 + SC vs SC alone
💡177LuPSMA617
⬆️ imaging based PFS (8.7 vs 3.4 m) HR for progression or ☠ 0.40
⬆️ OS (15.3 vs 11.3 mo) HR for ☠ 0.62
⬆️ AE but QoL was not affected https://t.co/JM1VK7hUaY

0

2

0

drhelennadel @drhelennadel

about 5 years ago

#snmmi2021 #nuclearmedicine #visiontrial fantastic late breaking session on results Vision trial. Thank you Drs. Morris @morr316 ,El-Haddad @GhassantelHadd1 , Hope @thomashopemd for an excellent informative session. If missed it watch on demand when available

0

3

1

0

SNMMI @SNM_MI

about 5 years ago

#SNMMI21 Late-Breaking Session Panelists Added! “PSMA Radioligand Therapy: Updates from the VISION Trial.” The Phase 3 #VISIONTrial is evaluating the efficacy of 177Lu-PSMA-617 (LuPSMA) in the treatment of patients with PSMA-positive metastatic castrate-resistant prostate cancer.

SNM_MI's tweet photo. #SNMMI21 Late-Breaking Session Panelists Added! “PSMA Radioligand Therapy: Updates from the VISION Trial.” The Phase 3 #VISIONTrial is evaluating the efficacy of 177Lu-PSMA-617 (LuPSMA) in the treatment of patients with PSMA-positive metastatic castrate-resistant prostate cancer. https://t.co/ra4p7EfTJ7

1

27

7

2

0

JNM @JournalofNucMed

about 5 years ago

#SNMMI21 Annual Meeting Late-Breaking Session: “PSMA Radioligand Therapy: Updates from the VISION Trial.” The Phase 3 #VISIONTrial is evaluating the efficacy of 177Lu-PSMA-617 (LuPSMA) in the treatment of patients with PSMA-positive metastatic castrate-resistant prostate cancer.

JournalofNucMed's tweet photo. #SNMMI21 Annual Meeting Late-Breaking Session: “PSMA Radioligand Therapy: Updates from the VISION Trial.” The Phase 3 #VISIONTrial is evaluating the efficacy of 177Lu-PSMA-617 (LuPSMA) in the treatment of patients with PSMA-positive metastatic castrate-resistant prostate cancer. https://t.co/fNJoO7BZXr

0

6

1

0

SNMMI @SNM_MI

about 5 years ago

#SNMMI21 Annual Meeting Late-Breaking Session! “PSMA Radioligand Therapy: Updates from the VISION Trial.” The Phase 3 #VISIONTrial is evaluating the efficacy of 177Lu-PSMA-617 (LuPSMA) in the treatment of patients with PSMA-positive metastatic castrate-resistant prostate cancer.

SNM_MI's tweet photo. #SNMMI21 Annual Meeting Late-Breaking Session! “PSMA Radioligand Therapy: Updates from the VISION Trial.” The Phase 3 #VISIONTrial is evaluating the efficacy of 177Lu-PSMA-617 (LuPSMA) in the treatment of patients with PSMA-positive metastatic castrate-resistant prostate cancer. https://t.co/YMYr7ZZKpG

0

22

8

0

Enrique Grande

@drenriquegrande

about 5 years ago · Madrid

Need to see more about baseline features but it looks like we have another tool for our #ProstateCancer patients 👏👏👏👏 Guided also by #theragnostic @OncoAlert #ASCO21 @DrJaVallejo @CentroGu #Visiontrial

JNM @JournalofNucMed

about 5 years ago

Impressive survival results from the Lu-177 PSMA-617 VISION trial: 38% reduced risk of death and 60% reduced risk of progression. #MedicalResearch #NucMed #PSMA #ProstateCancer https://t.co/0PcfEGDjWE